全文获取类型
收费全文 | 9379篇 |
免费 | 621篇 |
国内免费 | 919篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 93篇 |
妇产科学 | 17篇 |
基础医学 | 462篇 |
口腔科学 | 50篇 |
临床医学 | 962篇 |
内科学 | 582篇 |
皮肤病学 | 7篇 |
神经病学 | 175篇 |
特种医学 | 747篇 |
外科学 | 5416篇 |
综合类 | 1233篇 |
预防医学 | 175篇 |
眼科学 | 1篇 |
药学 | 379篇 |
2篇 | |
中国医学 | 194篇 |
肿瘤学 | 408篇 |
出版年
2024年 | 17篇 |
2023年 | 178篇 |
2022年 | 264篇 |
2021年 | 403篇 |
2020年 | 318篇 |
2019年 | 430篇 |
2018年 | 390篇 |
2017年 | 357篇 |
2016年 | 241篇 |
2015年 | 299篇 |
2014年 | 716篇 |
2013年 | 531篇 |
2012年 | 584篇 |
2011年 | 669篇 |
2010年 | 630篇 |
2009年 | 596篇 |
2008年 | 502篇 |
2007年 | 529篇 |
2006年 | 472篇 |
2005年 | 415篇 |
2004年 | 324篇 |
2003年 | 323篇 |
2002年 | 264篇 |
2001年 | 231篇 |
2000年 | 164篇 |
1999年 | 150篇 |
1998年 | 107篇 |
1997年 | 84篇 |
1996年 | 45篇 |
1995年 | 57篇 |
1994年 | 40篇 |
1993年 | 39篇 |
1992年 | 32篇 |
1991年 | 20篇 |
1990年 | 22篇 |
1989年 | 26篇 |
1988年 | 24篇 |
1985年 | 36篇 |
1984年 | 40篇 |
1983年 | 16篇 |
1982年 | 30篇 |
1981年 | 35篇 |
1980年 | 37篇 |
1979年 | 27篇 |
1978年 | 39篇 |
1977年 | 28篇 |
1976年 | 37篇 |
1975年 | 31篇 |
1974年 | 22篇 |
1973年 | 22篇 |
排序方式: 共有10000条查询结果,搜索用时 203 毫秒
1.
2.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):591-604.e3
ObjectivesGuidelines suggest aortic valve replacement (AVR) for low-risk asymptomatic patients. Indications for transcatheter AVR now include low-risk patients, making it imperative to understand state-of-the-art surgical AVR (SAVR) in this population. Therefore, we compared SAVR outcomes in low-risk patients with those expected from Society of Thoracic Surgeons (STS) models and assessed their intermediate-term survival.MethodsFrom January 2005 to January 2017, 3493 isolated SAVRs were performed in 3474 patients with STS predicted risk of mortality <4%. Observed operative mortality and composite major morbidity or mortality were compared with STS-expected outcomes according to calendar year of surgery. Logistic regression analysis was used to identify risk factors for these outcomes. Patients were followed for time-related mortality.ResultsWith 15 observed operative deaths (0.43%) compared with 55 expected (1.6%), the observed:expected ratio was 0.27 for mortality (95% confidence interval [CI], 0.14-0.42), stroke 0.65 (95% CI, 0.41-0.89), and reoperation 0.50 (95% CI, 0.42-0.60). Major morbidity or mortality steadily declined, with probabilities of 8.6%, 6.7%, and 5.2% in 2006, 2011, and 2016, respectively, while STS-expected risk remained at approximately 12%. Mitral valve regurgitation, ventricular hypertrophy, pulmonary, renal, and hepatic failure, coronary artery disease, and earlier surgery date were residual risk factors. Survival was 98%, 91%, and 82% at 1, 5, and 9 years, respectively, superior to that predicted for the US age-race-sex–matched population.ConclusionsSTS risk models overestimate contemporary SAVR risk at a high-volume center, supporting efforts to create a more agile quality assessment program. SAVR in low-risk patients provides durable survival benefit, supporting early surgery and providing a benchmark for transcatheter AVR. 相似文献
3.
《The Annals of thoracic surgery》2023,115(1):88-95
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity. 相似文献
4.
目的 研究胸段食管癌逆向调强放射治疗(IMRT)中累及野照射与扩大野照射对危及器官(OAR)受照剂量的影响。方法 40例胸段食管癌患者分别行累及野靶区勾画和扩大野靶区勾画并勾画危及器官,制定IMRT计划,评估2个计划的靶区适形指数(CI)和均匀性指数(HI)及危及器官的剂量学参数,剂量学参数比较采用配对t检验。结果 2种计划的PTV均能满足处方剂量要求,PTV在CI、HI上相近(P = 0.317、0.130)。两组间平均肺剂量、两肺V5、两肺V20、两肺V30、脊髓Dmean、心脏Dmean、心脏Dmax、心脏V30、心脏V40、心脏V60差异均存在统计学意义(P < 0.01)。结论 胸段食管癌患者行累及野照射与扩大野比较,可降低正常器官的受照剂量,从而降低放射性损伤风险。 相似文献
5.
6.
《European journal of surgical oncology》2020,46(6):982-990
IntroductionLung cancer is the leading cause of cancer-death worldwide. The U.S. Preventative Services Task Force (USPTSF) approved screening for current or former smokers aged 55–80 based on the results of the National Lung Screening trial (NLST). Following the NLST, new evidence has emerged from clinical trials and updates to previous trials prior to the anticipated update to the USPSTF guideline. We review the new evidence on lung cancer screening with low dose computed tomography (LDCT) and the surgical implications.MethodsA review of new literature was performed pertaining to lung cancer screening since implementation of UPSTF guidelines. Articles for inclusion were identified by both authors’, then search of the Pubmed and Cochrane database was performed from January 1st, 2013 through February 4th, 2020 using the MeSH search terms: “lung cancer”; “screening”; “low dose CT”. The results of these studies are summarized.ResultsWe identified multiple prospective randomized control trials and meta-analysis since the NLST supporting lung cancer-specific mortality with screening. We identified new nodule classification systems and the development of risk-models which may reduce false positive rates and identify high risk patients not currently eligible for screening. Finally, we discussed the surgical implications of screening.ConclusionNew data supports NLST findings and show ongoing benefit to LDCT for lung cancer screening. Standardized LDCT screening classification has been shown to reduce harm and lower false positive rates. Further study is needed regarding use of risk-modeling. Screening will require an increase in the thoracic workforce to accommodate the amount of surgically operable cancers. 相似文献
7.
《Clinical lung cancer》2020,21(2):160-170
IntroductionPulmonary carcinosarcoma (PC) is a rare malignant neoplasm composed of epithelial and mesenchymal components. It accounts for < 1% of thoracic cancers and is not fully understood. This study examined Surveillance, Epidemiology, and End Results (SEER) data to describe demographic and clinical characteristics of patients with PC and assessed survival outcomes by treatment modality and stage.Patients and MethodsSEER data were reviewed to identify patients diagnosed with primary PC (1973-2012). Overall survival (OS) and disease-specific survival (DSS) were analyzed by univariate/multivariable Cox proportional hazards models and Kaplan-Meier methods.ResultsA total of 411 patients were included. Median age was 67 (range, 24-96) years. Disease stage at the time of initial diagnosis was known for 74.7% of the identified patients (307/411). Of these patients, 23.1% had localized disease. Survival was significantly better for patients with localized disease (OS: 31 vs. 6 months, P < .001; DSS: 54 vs. 8 months, P < .001). Additionally, patients who received surgery alone had significantly improved OS (20 months; P < .001) and DSS (32 months; P < .001) compared to patients who received combined surgery and radiotherapy (OS: 7 months; DSS: 8 months) or radiotherapy alone (OS: 4 months; DSS: 4 months).ConclusionTreatment with surgery alone resulted in superior survival outcomes compared to other treatment modality combinations, regardless of patient age and disease stage. Within the limitations of this study, providers may wish to consider these findings when devising patient treatment plans. 相似文献
8.
9.
10.
Theodoros Kratimenos Constantine N. Antonopoulos Dimitrios Tomais Panagiotis Dedeilias Vasileios Patris Ilias Samiotis John Kokotsakis Dimosthenis Farsaris Michalis Argiriou 《Journal of vascular surgery》2019,69(4):996-1002.e3